{"id":992,"date":"2025-11-17T07:39:17","date_gmt":"2025-11-17T07:39:17","guid":{"rendered":"https:\/\/snips.nutrifytoday.com\/blog\/?p=992"},"modified":"2025-11-17T07:39:17","modified_gmt":"2025-11-17T07:39:17","slug":"fda-approves-cobenfy-a-breakthrough-antipsychotic-with-new-mechanism-for-schizophrenia-treatment","status":"publish","type":"post","link":"https:\/\/snips.nutrifytoday.com\/blog\/fda-approves-cobenfy-a-breakthrough-antipsychotic-with-new-mechanism-for-schizophrenia-treatment\/","title":{"rendered":"FDA Approves Cobenfy: A Breakthrough Antipsychotic with New Mechanism for Schizophrenia Treatment"},"content":{"rendered":"\n<p>The FDA has approved Cobenfy (xanomeline and trospium chloride) for treating schizophrenia in adults, marking a breakthrough as the first antipsychotic to target cholinergic receptors instead of dopamine receptors. Schizophrenia, a chronic mental illness affecting about 1% of Americans, causes psychotic symptoms and cognitive difficulties, and is a leading cause of disability globally. Cobenfy&#8217;s efficacy was demonstrated in two 5-week clinical trials where participants saw a significant reduction in symptoms. However, it carries warnings for potential side effects, including urinary retention, liver and kidney issues, and is not recommended for patients with certain pre-existing conditions.<\/p>\n\n\n\n<p>Source: <a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-drug-new-mechanism-action-treatment-schizophrenia\">https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-drug-new-mechanism-action-treatment-schizophrenia<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA has approved Cobenfy (xanomeline and trospium chloride) for treating schizophrenia in adults, marking a breakthrough as the first antipsychotic to target cholinergic receptors instead of dopamine receptors. Schizophrenia, a chronic mental illness affecting about 1% of Americans, causes psychotic symptoms and cognitive difficulties, and is a leading cause of disability globally. Cobenfy&#8217;s efficacy [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-992","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/snips.nutrifytoday.com\/blog\/wp-json\/wp\/v2\/posts\/992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/snips.nutrifytoday.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/snips.nutrifytoday.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/snips.nutrifytoday.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/snips.nutrifytoday.com\/blog\/wp-json\/wp\/v2\/comments?post=992"}],"version-history":[{"count":1,"href":"https:\/\/snips.nutrifytoday.com\/blog\/wp-json\/wp\/v2\/posts\/992\/revisions"}],"predecessor-version":[{"id":993,"href":"https:\/\/snips.nutrifytoday.com\/blog\/wp-json\/wp\/v2\/posts\/992\/revisions\/993"}],"wp:attachment":[{"href":"https:\/\/snips.nutrifytoday.com\/blog\/wp-json\/wp\/v2\/media?parent=992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/snips.nutrifytoday.com\/blog\/wp-json\/wp\/v2\/categories?post=992"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/snips.nutrifytoday.com\/blog\/wp-json\/wp\/v2\/tags?post=992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}